What Drives Early Recurrence in Intracranial Atherosclerosis: A Multicenter Study
Abstract Body: Background: Intracranial Atherosclerosis carries a high recurrence rate. Single center studies have shown that impaired distal perfusion is a driver of early recurrence. In this study, we aim to identify predictors of 30-day ischemic stroke recurrence in a multicenter cohort.
Methods: This is a pooled analysis of individual patient data from four comprehensive stroke centers of hospitalized patients with symptomatic intracranial arterial stenosis (50-99%) of the intracranial ICA and proximal middle cerebral artery (M1 or proximal M2). The study outcome was recurrent ischemic stroke by day 30. We compared baseline demographics (age, sex, race, ethnicity), vascular risk factors (hypertension, hyperlipidemia, diabetes, atrial fibrillation), NIHSS score, last known well to arrival, home medications (aspirin, anticoagulation), imaging variables (prior infarct in territory, degree of stenosis, perfusion delay volume, borderzone infarct pattern), and in-hospital treatments (thrombolysis, dual antiplatelet therapy, statin, permissive hypertension). Variables with p<0.1 on univariate analyses were included in a Cox regression model to identify important outcome predictors. Missing data was imputed as absent for categorical variables and at the median for continuous variables.
Results: We identified 274 patients hospitalized with symptomatic intracranial stenosis who met the inclusion criteria; 70 patients (25.5%) had a recurrent ischemic stroke within 30 days. In unadjusted Cox regression models, predictors of early recurrence were mismatch volume of 25 ml or greater at T max of 6 seconds (HR 2.19 95% CI 1.37-3.51, p = 0.001), 70-99% (vs. 50-69%) stenosis (HR 3.34 95% CI 1.05-10.60, p = 0.041), diabetes (HR 1.60 95% CI 1.0-2.57, p = 0.048), home aspirin (HR 1.77, 95% CI 1.06-2.95, p = 0.029), and home statin (HR 1.73 95% CI 1.04-2.89, p = 0.039). In adjusted Cox regression, the only predictors of 30-day recurrence were T max 6 mismatch volume 25 mL or more (adjusted HR 2.14 95% CI 1.27-3.61, p = 0.004), and 70-99% (vs. 50-69%) stenosis (adjusted HR 3.37 95% CI 1.05-10.84, p = 0.041).
Conclusions: One in four medically treated patients with proximal anterior circulation symptomatic ICAS have a recurrent stroke within 30 days with impaired distal perfusion being an important driver of recurrence. Studies are needed to validate these findings and test reperfusion strategies in those with impaired perfusion.
Yaghi, Shadi
( Brown University
, Providence
, Rhode Island
, United States
)
De Havenon, Adam
( Yale University
, New Haven
, Connecticut
, United States
)
Prabhakaran, Shyam
( University of Chicago
, Chicago
, Illinois
, United States
)
Liebeskind, David
( UCLA
, Los Angeles
, California
, United States
)
Nguyen, Thanh
( Boston University
, Boston
, Massachusetts
, United States
)
Furie, Karen
( Department of Neurology
, Providence
, Rhode Island
, United States
)
Wu, Moxin
( Brown University
, Providence
, Rhode Island
, United States
)
Shu, Liqi
( Brown University
, Providence
, Rhode Island
, United States
)
Stipanovich, Ava
( Brown University
, Providence
, Rhode Island
, United States
)
Heldner, Mirjam
( Bern
, Bern
, Switzerland
)
Goldstein, Eric
( Henry Ford
, Detriot
, Michigan
, United States
)
Kvernland, Alexandra
( NYU Langone
, New York
, New York
, United States
)
Raz, Eytan
( NYU Medical Center
, New York
, New York
, United States
)
Hakim, Arsany
( Bern
, Bern
, Switzerland
)
Author Disclosures:
Shadi Yaghi:DO NOT have relevant financial relationships
| Piotr Radojewski:No Answer
| Pasquale Mordasini:No Answer
| Kateryna Antonenko:No Answer
| William Almiri:DO NOT have relevant financial relationships
| Adam de Havenon:DO have relevant financial relationships
;
Research Funding (PI or named investigator):NIH/NINDS:Active (exists now)
; Researcher:UptoDate:Active (exists now)
; Individual Stocks/Stock Options:Certus:Active (exists now)
; Individual Stocks/Stock Options:TitinKM:Active (exists now)
; Consultant:Novo Nordisk:Active (exists now)
; Research Funding (PI or named investigator):AAN:Active (exists now)
| Shyam Prabhakaran:No Answer
| David Liebeskind:DO NOT have relevant financial relationships
| Thanh Nguyen:DO have relevant financial relationships
;
Other (please indicate in the box next to the company name):American Stroke Association:Active (exists now)
; Advisor:Aruna Bio:Past (completed)
; Advisor:Brainomix:Active (exists now)
| Karen Furie:DO have relevant financial relationships
;
Consultant:Janssen/BMS:Active (exists now)
| Moxin Wu:DO NOT have relevant financial relationships
| Liqi Shu:DO NOT have relevant financial relationships
| Ava Stipanovich:DO NOT have relevant financial relationships
| Mirjam Heldner:DO NOT have relevant financial relationships
| Eric Goldstein:DO NOT have relevant financial relationships
| Alexandra Kvernland:DO NOT have relevant financial relationships
| Eytan Raz:DO have relevant financial relationships
;
Consultant: Balt, Cerenovus, Imperative Care, Phenox, QApel, Siemens, Medtronic, Microvention, Route92, Vasorum.:Active (exists now)
| Arsany Hakim:DO NOT have relevant financial relationships